After accounting for other factors like age, sex, and how long someone was on medication, the level of thyroid-stimulating antibodies at the time of stopping treatment is the single strongest factor that predicts whether Graves disease will return.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
A meta-analysis of multivariate models from multiple studies could determine whether TSAb consistently emerges as the strongest independent predictor across diverse populations and assay methods.
A systematic review and meta-analysis of all multivariate Cox regression models from prospective cohort studies measuring TSAb at antithyroid drug withdrawal, extracting hazard ratios adjusted for age, sex, goiter, treatment duration, and other clinical variables, with pooled effect estimates.
An RCT could test whether using TSAb to guide treatment decisions (e.g., early RAI) reduces relapse more than using other predictors, confirming its clinical superiority.
A multicenter RCT of 500 adults with Graves disease in euthyroidism after antithyroid drugs, randomized to treatment decisions based on TSAb level vs. decisions based on clinical factors alone (age, goiter, duration). Primary outcome: relapse-free survival at 24 months.
A prospective cohort study could validate whether TSAb remains the only significant independent predictor in a larger, more diverse population.
A prospective cohort study of 400 adults with Graves disease achieving euthyroidism after antithyroid drugs, measuring TSAb at withdrawal and collecting data on age, sex, goiter, TAO, treatment duration, and fT4, then following them for 24 months with blinded thyroid function tests and performing multivariate Cox regression.
A case-control study could compare the odds of having high TSAb at withdrawal between relapsed and non-relapsed patients while adjusting for confounders.
A case-control study of 120 patients with Graves disease who relapsed within 24 months of drug withdrawal and 120 matched controls who remained in remission, comparing TSAb levels at withdrawal and adjusting for age, sex, goiter, and treatment duration using logistic regression.
A cross-sectional study could assess whether TSAb levels correlate with clinical factors at withdrawal but cannot determine predictive independence.
A cross-sectional study measuring TSAb levels and collecting data on age, sex, goiter, and treatment duration in 600 adults with Graves disease at the time of antithyroid drug withdrawal.